FDA Accepts IND Application for ST-001 in Relapsed/Refractory SCLC

SciTech Development Announces 2nd FDA Approval of a Phase 1 a/b IND For ST-001. New IND Targets the Treatment of Relapsed/Refractory Small Cell Lung Cancer Following Its Previous Approval in the Treatment of T-Cell NHL

GROSSE POINTE FARMS, Mich., April 8, 2025 /PRNewswire/ -- SciTech Development, Inc., a clinical-stage oncology company pioneering innovative cancer therapeutics, is thrilled to announce that the U.S. Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application…

FDA Accepts IND Application for ST-001 in Relapsed/Refractory SCLC

Investigators will assess the safety, pharmacology, and maximum tolerated dose of ST-001 in relapsed/refractory SCLC as part of a phase 1a/1b trial.

FDA Clears IND Application for ST-001 in SCLC

ST-001, an intravenous nanoformulation of fenretinide, will be evaluated in a phase 1a/1b small cell lung cancer trial.